News & Media

Vancouver, BC (November 30, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has received authorizations for its Phase 2B Clinical Trial Applications from the regulatory authorities of China, Singapore, Taiwan, Korea, USA, and Canada.

Vancouver, BC (September 22, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that a scientific poster on the Company’s lead drug candidate, Halneuron, was presented at the International Association for the Study of Pain (IASP) World Congress on

Vancouver, BC (August 31, 2022) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that a poster presentation on the Company’s lead drug candidate Halneuron was accepted for presentation at the International Association for the Study of Pain (IASP)

Vancouver, BC (April 30, 2021) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for chronic pain, announced the publication of two clinical studies in a special issue of the Toxins Journal, Tetrodotoxin (TTX) as a Therapeutic Agent.

Vancouver, BC (March 30, 2018) ‐ WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing HalneuronTM (Tetrodotoxin or TTX) for pain, today announced the successful completion of the thorough electrocardiogram (“ECG”) study of Halneuron conducted in healthy volunteers.